Prise en charge des sténoses et thromboses de l’Artère Fémorale superficielle

Recommandations TASC II

nom année type patients 1an 2ans 3ans 5ans

green 2000 prothese 240 78 44/68

klinkert 2003 prothese 76 52/57

veine 75 76/80

Johnson WC

2001 veine 226 81a 73a

HUV 261 70a 53a

prothese 265 69 39a

Archie JP Jr.

1994 veine 232 87 81

prothese 62 54 48

NOM patients lesion occlusion

stenose stent 6 12 24 36

stanley1996

176 200 45 58 58 46 38

cejna1999

176 70 27 43 33 79/86 a 72/70 a

soder2000

60 188 67 121 0 48

schneider2000

318 411 411 0 82/82 33/65

jamsen2002

173 218 120 98 2 37 31

bequemin2003

227 227 50 177 nitinol 92/96 a 89/93 a 82/80 a

baril2008

125 149 58.9 47.9

Schillinger 2006

104 nitinol 55

NOM patients lesion occlusion

stenose stent 6 12 24 36 48

Bouffi2013

58 SIA 77/90 70/90 64/90

Superb2012

264 266 60 206 nitinol 78.5

Resilient2010

134 153 41 112 nitinol 72.2

Durability II2013

287 287 40 247 nitinol 67.7

Complete SFA2012

196 213 nitinol 73.1

SUPER2012

150 150 140 10 nitinol 42.6 /46 b

VIBRANT2013

148 Viabahn 25.9/24b78/89a

VIPER2013

113 119 67 52 viabahn 73/92

Mc Quade2010

50 nitinol 72 63 63 59

Traitement endovasculaire :réinterventions

Paclitaxel-Coated Versus Uncoated Balloon Angioplasty Reduces Target Lesion Revascularization in Patients With Femoropopliteal Arterial Disease: A Meta-Analysis of Randomized Trials Salvatore Cassese

Traitement endovasculaire :réinterventions

Paclitaxel-Coated Versus Uncoated Balloon Angioplasty Reduces Target Lesion Revascularization in Patients With Femoropopliteal Arterial Disease: A Meta-Analysis of Randomized Trials Salvatore Cassese

morbi-mortalité